Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FF 10501

Drug Profile

FF 10501

Alternative Names: FF 10501 01; FF-10501; IMPDH inhibitor FF-10501

Latest Information Update: 23 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FUJIFILM Holdings Corporation
  • Developer FUJIFILM Holdings Corporation; Strategia Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myelodysplastic syndromes
  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia

Most Recent Events

  • 23 Oct 2019 Fujifilm Pharmaceuticals completes a phase I/II trial in Acute myeloid leukaemia, Chronic myelomonocytic leukaemia and Myelodysplastic syndromes (Second line therapy or greater) in USA (NCT02193958)
  • 28 May 2019 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes in Japan (PO, Tablet)
  • 07 Feb 2019 Phase-II clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in USA (PO) (FUJIFILM Holdings Corporation annual report, Febaruary 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top